Advertisement

Angiogenesis

, Volume 10, Issue 2, pp 71–76 | Cite as

Ocular drug development - Future Directions

  • David SherrisEmail author
Original Paper

Abstract

Technology has caught up with retinal diseases of neovasculature. Work with anti-cancer, anti-angiogenic agents has fueled the way for ocular therapeutics. The market size for age-related macular degeneration and diabetic retinopathy is huge. Fifteen million people in the United States alone have age-related macular degeneration with 2 million new cases each year (1). About 20.8 million people in the United States have diabetes. Of those, 14.6 million are diagnosed and 6.2 million are undiagnosed (2). Of patients who have had type 1 diabetics for more than 20 years, 50% will have proliferative diabetic retinopathy (3). Between 60% and 80% of type 2 diabetics will manifest retinopathy after 15 years, and 20% will progress to proliferative retinopathy after 25 years of duration (4). Big pharma and biotech were complacent in developing drugs capable of having effect on ocular neovascular diseases even though technologies were available, at least on the research level, long before there was serious activity to bring such technologies to the clinic. Finally, over the last three years, triple digit million dollar business development deals have been consummated, mostly for VEGF-A targeted modalities. Such biodollar partnerships were the eye openers which have now led to a concerted action to develop ocular drugs to combat ocular neovascularization. Anti-VEGF-A technologies do not constitute the whole story. Agents with broader activity, activity that occurs later down the angiogenic pathway and those drugs which are capable to synergize with anti-VEGF-A technologies will dominate the next wave in ocular diseases of neovascularization and will lead the next round of significant business development deals.

Keywords

Angiogenesis Angiogenic Vascular targeting agent VTA Vascular disrupting agent VDA Vascular maturation agent VMA Diabetic retinopathy Macular degeneration Ocular Retina Vascularization Neovascularization Capillary Genentech Eyetech Lucentis Avastin Macugen Novartis Palomid Paloma Pharmaceuticals VEGF PDGF FGF HIF-1a Kinase Folkman Sherris 

References

  1. 1.
    AMD Alliance International. AMD: A Policy Blueprint to Protect America’s At-Risk Seniors. September 2006. http://www.amdalliance.org/documents/TSCAMDWhitePaper9-20062.pdf
  2. 2.
    National Diabetes Information Clearinghouse House, Diabetes prevention program, NIH publication, August 2006, No. 06–5099Google Scholar
  3. 3.
    Klein R, Klein BE, Moss SE et al (1984) The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 102:520–6PubMedGoogle Scholar
  4. 4.
    Klein R, Klein BE, Moss SE et al (1984) The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 102:527–32PubMedGoogle Scholar
  5. 5.
    http://www.clinicaltrials.govGoogle Scholar
  6. 6.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182–6PubMedCrossRefGoogle Scholar
  7. 7.
    Taniguchi S, Takeoka M, Ehara T, Hashimoto S, Shibuki H, Yoshimura N, Shigematsu H, Takahashi K, Katsuki M (2001) Structural fragility of blood vessels and peritoneum in calponin h1-deficient mice, resulting in an increase in hematogenous metastasis and peritoneal dissemination of malignant tumor cells. Cancer Res 61(20):7627–34PubMedGoogle Scholar
  8. 8.
    Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160(3):985–1000PubMedGoogle Scholar
  9. 9.
    Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT (2006) Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am J Pathol 168(6):2036–53PubMedCrossRefGoogle Scholar
  10. 10.
    Neri D, Carnemolla B, Nissim A, Leprini A, Querze G, Balza E, Pini A, Tarli L, Halin C, Neri P, Zardi L, Winter G (1997) Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform. Nat Biotechnol 15(12):1271–5PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2007

Authors and Affiliations

  1. 1.Sherris Pharma PartnersJamaica PlainUSA

Personalised recommendations